Patents by Inventor Daniel Mark Ledger

Daniel Mark Ledger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhalable particles
    Patent number: 11759420
    Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: September 19, 2023
    Assignee: CRYSTEC LTD
    Inventors: Daniel Mark Ledger, Linda Sharon Daintree, Peter York
  • CRYSTAL FORMS OF TETRAHYDRO-N, N-DIMETHYL-2, 2-DIPHENYL-3-FURANMETHANAMINE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230278973
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX19-144) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Application
    Filed: May 8, 2023
    Publication date: September 7, 2023
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York, Alani Selvey
  • Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
    Patent number: 11661405
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: May 30, 2023
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York, Alani Selvey
  • INHALABLE PARTICLES
    Publication number: 20220331243
    Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
    Type: Application
    Filed: May 5, 2022
    Publication date: October 20, 2022
    Inventors: Daniel Mark LEDGER, Linda Sharon DAINTREE, Peter YORK
  • Inhalable particles
    Patent number: 11351115
    Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 7, 2022
    Assignee: CRYSTEC LTD
    Inventors: Daniel Mark Ledger, Linda Sharon Daintree, Peter York
  • CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20210220321
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Application
    Filed: April 5, 2021
    Publication date: July 22, 2021
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
  • Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
    Patent number: 10966952
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: April 6, 2021
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
  • Inhalable Particles
    Publication number: 20200230053
    Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
    Type: Application
    Filed: December 16, 2019
    Publication date: July 23, 2020
    Inventors: Daniel Mark Ledger, Linda Sharon Daintree, Peter York
  • CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20190350892
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Application
    Filed: July 29, 2019
    Publication date: November 21, 2019
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
  • Crystal forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
    Patent number: 10413519
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3 -furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2 -diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 17, 2019
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
  • Method of preparing itraconazole preparation
    Patent number: 10258574
    Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: April 16, 2019
    Assignees: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.
    Inventors: Xuezhi Yin, Linda Sharon Daintree, Sheng Ding, Daniel Mark Ledger, Bing Wang, Wenwen Zhao, Wei Wu, Jiansheng Han
  • METHOD FOR PREPARING ITRACONAZOLE PREPARATION
    Publication number: 20180263912
    Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.
    Type: Application
    Filed: September 8, 2015
    Publication date: September 20, 2018
    Applicants: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.
    Inventors: Xuezhi YIN, Linda Sharon DAINTREE, Sheng DING, Daniel Mark LEDGER, Bing WANG, Wenwen ZHAO, Wei WU, Jiansheng HAN
  • CRYSTAL FORMS OF tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20180169060
    Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
    Type: Application
    Filed: July 19, 2016
    Publication date: June 21, 2018
    Inventors: Linda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York
  • Improvements Relating To Inhalable Particles
    Publication number: 20170056325
    Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.
    Type: Application
    Filed: February 13, 2015
    Publication date: March 2, 2017
    Inventors: Daniel Mark Ledger, Linda Sharon Daintree, Peter York